Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combined Sorafenib for Advanced Hepatocellular Carcinoma With Portal Vein Invasion

Peng Liubao, Wan Xiaomin, Tan Chongqing, Jon Karnon, Chen Gannong, Li Jianhe, Cui Wei, Luo Xia, Cao Junhua, Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide. PharmacoEconomics. ,vol. 27, pp. 873- 886 ,(2009) , 10.2165/11314750-000000000-00000

JC Weeks, D Romanus, JE Herndon, D Schrag, RJ Mayer, N Kemeny, PCN13 COST-EFFECTIVENESS OF HEPATIC ARTERY INFUSION FOR METASTATIC COLORECTAL CANCER (CALGB 9481) Value in Health. ,vol. 8, ,(2005) , 10.1016/S1098-3015(10)67251-8

Ann-Lii Cheng, Yoon-Koo Kang, Zhendong Chen, Chao-Jung Tsao, Shukui Qin, Jun Suk Kim, Rongcheng Luo, Jifeng Feng, Shenglong Ye, Tsai-Sheng Yang, Jianming Xu, Yan Sun, Houjie Liang, Jiwei Liu, Jiejun Wang, Won Young Tak, Hongming Pan, Karin Burock, Jessie Zou, Dimitris Voliotis, Zhongzhen Guan, None, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology. ,vol. 10, pp. 25- 34 ,(2009) , 10.1016/S1470-2045(08)70285-7

Boris W. Kuvshinoff, Cost‐effectiveness of hepatic artery infusion chemotherapy Cancer. ,vol. 83, pp. 837- 838 ,(1998) , 10.1002/(SICI)1097-0142(19980901)83:5<837::AID-CNCR4>3.0.CO;2-F

Masami Minagawa, Masatoshi Makuuchi, Tadatoshi Takayama, Norihiro Kokudo, Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Annals of Surgery. ,vol. 238, pp. 703- 710 ,(2003) , 10.1097/01.SLA.0000094549.11754.E6

Beom Kyung Kim, Jun Yong Park, Hye Jin Choi, Do Young Kim, Sang Hoon Ahn, Ja Kyung Kim, Do Youn Lee, Kwang Hoon Lee, Kwang-Hyub Han, Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma Journal of Cancer Research and Clinical Oncology. ,vol. 137, pp. 659- 667 ,(2011) , 10.1007/S00432-010-0917-5

Christopher McCabe, Karl Claxton, Anthony J Culyer, The NICE cost-effectiveness threshold: what it is and what that means. PharmacoEconomics. ,vol. 26, pp. 733- 744 ,(2008) , 10.2165/00019053-200826090-00004

Maïté Lewin, Laetitia Fartoux, Alexandre Vignaud, Lionel Arrivé, Yves Menu, Olivier Rosmorduc, The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study European Radiology. ,vol. 21, pp. 281- 290 ,(2011) , 10.1007/S00330-010-1914-4

Xiaoyun Zhang, Chuan Li, Tianfu Wen, Lunan Yan, Bo Li, Jiayin Yang, Wentao Wang, Mingqing Xu, Wusheng Lu, Li Jiang, None, Appropriate treatment strategies for intrahepatic recurrence after curative resection of hepatocellular carcinoma initially within the Milan criteria: according to the recurrence pattern European Journal of Gastroenterology & Hepatology. ,vol. 27, pp. 933- 940 ,(2015) , 10.1097/MEG.0000000000000383

M Connock, J Round, S Bayliss, S Tubeuf, W Greenheld, D Moore, Sorafenib for the treatment of advanced hepatocellular carcinoma. Health Technology Assessment. ,vol. 14, pp. 17- 21 ,(2010) , 10.3310/HTA14SUPPL1/03